Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1995-06-07
2003-11-25
Eyler, Yvonne (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C436S536000, C436S547000, C436S548000, C530S300000, C530S350000, C530S387700, C530S387900, C530S388220, C530S388800, C530S389700, C530S391300, C530S391700, C424S138100, C424S139100, C424S143100, C424S155100, C424S179100, C424S181100, C424S183100, C424S185100
Reexamination Certificate
active
06653084
ABSTRACT:
BACKGROUND OF THE INVENTION
Technical Field
The present invention is related to the cloning, isolation and partial characterization of a hitherto unidentified human gene. More particularly, the present invention is related to the preparation and identification of a v-erbB related human gene that is a new member of the tyrosine kinase encoding family of genes and is amplified in a human mammary carcinoma.
State of the Art
A number of genes have been identified as retroviral oncogenes that are responsible for inducing tumors in vivo and transforming cells in vitro (Land et al.,
Science
222:771-778, 1983). Some of them apparently encode transforming proteins that share a kinase domain homologous to that of pp60
src
a tyrosine-specific protein kinase. The cellular cognate, encoded by the c-src gene, also exhibits tyrosine-specific kinase activity. Of particular interest is the fact that tyrosine-specific kinases are also encoded by other genes for several receptors for polypeptide growth factors, including the receptors for epidermal growth factor (EGF) (Cohen et al.,
J. Biol. Chem
. 255:4834-4842, 1980), platelet-derived growth factor (PDGF) (Nishimura et al.,
Proc. Natl. Acad. Sci. USA
79:4303-4307, 1982), insulin (Kasuga et al.,
Nature
298:667-669, 1982), and insulin-like growth factor I (Rubin et al.,
Nature
305:438-440, 1983). This implies a possible link between the action of the growth factor-receptor complex and the oncogene products with tyrosine-specific kinase activity.
Recent analysis of the v-erbB gene and the EGF receptor gene indicates that the v-erbB gene is a part of the EGF receptor gene and codes for the internal domain and transmembrane portion of the receptor (Yamamoto et al.,
Cell
35:71-78, 1983; Downward et al.,
Nature
307:521-527, 1984; Ullrich et al.,
Nature
309:418425, 1984). These findings, together with the extensive identity of the amino acid sequences of the v-sis protein and platelet-derived growth factor (Waterfield et al.,
Nature
304:35-39, 1983; Doolittle et al.,
Science
221:275-277, 1983), suggest that some viral oncogene products mimic the action of the polypeptide growth factor-receptor complex in activating a cellular pathway involved in cell proliferation and tumor formation.
Genetic alterations affecting proto-oncogenes of the tyrosine kinase family may play a role in spontaneous tumor development. A specific translocation affecting the c-abl locus, for example, is associated with chronic myelogenous leukemia (de Klein et al.,
Nature
300:765, 1982; Collins et al.,
Proc. Natl Acad. Sci. USA
80:4813, 1983). Several recent studies have also documented amplification or rearrangement of the gene for the EGF receptor in certain human tumors (Libermann et al.,
Nature
313:144, 1985), or tumor cell lines (Ullrich et al.,
Nature
309:418, 1984; Lin et al.,
Science
224:843, 1984). However, a gene that is a new member of the tyrosine kinase family and is amplified in a human mammary carcinoma and is closely related to, but distinct from the EGF receptor gene, has not heretofore been known.
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide a novel, cloned, human gene having the nucleotide sequence as shown in FIG.
1
and described more fully herein infra.
It is a further object of the present invention to provide products, e.g. various RNAs and/or polypeptides encoded by the cloned gene.
It is a still further object of the present invention to provide antibodies, either polyclonal or monoclonal, directed against the protein product encoded by said gene and a diagnostic kit containing said antibodies for the detection of carcinomas.
It is another object of the present invention to provide complementary DNA (cDNA) clones homologous to the messenger RNA (mRNA) encoded by the cloned gene, said cDNA clones being capable of expressing large amounts of corresponding protein in a heterologous vector system, such as bacteria, yeast, eukaryotes and the like.
It is yet another object of the present invention to produce a transformed cell or organism capable of expressing said gene by incorporating said gene or a part thereof into the genome of said cell, vector or organism.
It is a still further object of the present invention to provide nucleic acid probes and/or antibody reagent kits capable of detecting said gene or a product thereof.
Other objects and advantages of the present invention will become apparent as the detailed description of the invention proceeds.
REFERENCES:
patent: 4520226 (1985-05-01), Neville, Jr. et al.
patent: 4659839 (1987-04-01), Nicolotti et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5629197 (1997-05-01), Ring et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: WO 93/16185 (1993-08-01), None
Goding, J.W., 1983, Monoclonal Antibodies: Principles and Practice, Academic Press, Inc.: London, UK, pp. 3, 56-97, 178, 180-181, 208-261.*
Waterfield et al., A monoclonal antibody to the human epidermal growth factor receptor, J. Cell. Biochem., 20: 149-161, 1982.*
Ring et al. “Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2”Mol. Immunol. 28(8):915-917, 1991.
Ring et al. “Distribution and Physical Properties of BCA200, a Mr200,000 Glycoprotein Selectively Associated with Human Breast Cancer”Cancer Res. 49:3070-3080, Jun. 1, 1989.
Coussens et al. “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location withneuOncogene”Science230:1132-1139, Dec. 6, 1985.
Pirker et al. “Characterization of Immunotoxins Active Against Ovarian Cancer Cell Lines”J. Clin. Invest. 76:1261-1267, Sep. 1985.
Frankel et al. “Tissue Distribution of Breast Cancer-Associated Antigens Defined by Monoclonal Antibodies”J. Biol. Resp. Modifiers4:273-286, 1985.
Bjorn et al. “Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins”Cancer Res. 45:1214-1221, Mar. 1985.
AA. King, et al. Cell Membr. Cancer Proc. Intl. Workshop, 2nd., pp. 411-416 (1985).
BB. Semba, et al. “A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma” PNAS, USA 82: 6497-6501 (Oct., 1985).
CC. Schechter, et al. “The neu oncogene: an erb-B-related gene encoding a 185,000-Mrtumour antigen” Nature 312: 513-516 (Dec. 6, 1984).
EE. Schechter, et al. Science 229: 976-8 (Sep. 6, 1985).
FF. King, et al. “Oncogenes as growth factors . . . erbB-related gene” in Chem. Abstracts 104(17): 142890e (Apr. 28, 1986) (corresponds to AA).
Paik, S. et al. “Pathologic Findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer” J. of Clinical Oncology (1990) 8:103-112.
King, C.B. et al. “Heterogeneous Expression of erbB-2 Messenger RNA in Human Breast Cancer” Cancer Research(1989) 49:4185-4191.
Park, J-B. et al. “Amplification, Overexpression, and Rearrangement of erbB-2 Protooncogene in Primary Human Stomach Carcinomes” Cancer Research (1989) 49:6605-6609.
King, C.B. et al. “Implications of erbB-2 overexpression for basic science and clinical medicine” seminars in Cancer Biology (1990) 1:329-337.
Berger, M.S. et al. “Correlation of c-erbB-2 Gene Amplification and Protein Expression in Human Breast Carcinoma with Model Status and Nuclear Grading” Cancer Research (1988) 48:1238-1243.
A. Ullrich et al., “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells,” Nature (1984) vol. 309, pp. 418-425.
King et al., Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma,Science, (1985) 229:974-976.
Kraus et al., Overexpression of the EGF Receptor-Related Proto-Oncogene erbB-2 in Human Mammary Tumor Cell Lines . . .The EMBO Journal, (1987) 6:605-610.
Di Foire
Aaronson Stuart A.
King C. Richter
Kraus Matthias H.
Eyler Yvonne
Kaufman Claire M.
Needle & Rosenberg P.C.
The United States of America as represented by the Department of
LandOfFree
Anti-erbB-2 antibodies to human receptor related to but... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-erbB-2 antibodies to human receptor related to but..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-erbB-2 antibodies to human receptor related to but... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3115018